Nutritional status of pediatric patients living with human immunodeficiency virus in Bogotá, Colombia

Julieth García-Ortiz1, Iván Mauricio Villamil-Morales2,*, Juan Carlos López-García3.

Abstract

Background: Undernutrition is frequent among children living with HIV in developing countries. An interaction between malnutrition and HIV pediatric infection remains incompletely characterized in Colombia.

Methodology: Retrospective longitudinal study, descriptive in nature, in 28 patients with a diagnosis of HIV infection, less than 18 years of age and receiving antiretroviral therapy. Variables were retrieved from clinical records at start of antiretroviral therapy and after 12 months. Statistical analysis was exploratory.

Results: 4 out of 28 patients were stunted (14.3%; 95%CI: 1.3 – 27.2), 2 out of 7 patients were wasted (28.6%; 95%CI: 0 – 62), 5 out of 17 patients were underweight (27.8%; 95%CI: 7.1 – 48.5) and 4 out of 28 patients had thinness (29.6%; 95%CI: 12.4 – 46.8). No clinically relevant anthropometric change was detected during follow-up. Anemia prevalence was 52% and 82% of patients had some degree of dyslipidemia. Both viral load (p=0.001) and CD4 count (p=0.01), significantly increased and the proportion of patients with therapeutic failure remained invariable during follow-up.

Conclusion: Malnutrition is frequent and its prevalence might have decreased. HIV program improved medical control of the disease, with stable therapeutic failure rates that were comparable with previous reports. Nonetheless, anemia and dyslipidemia remain to be a paramount therapeutic challenge.

Keywords: Human immunodeficiency virus, malnutrition, antiretroviral therapy, therapeutic failure, pediatrics.

Nutritional status in children with HIV

Introduction

More than a half of children who start antiretroviral therapy (ART) in developing countries are underweight and malnutrition has been associated to triplication of mortality during the first month of ART1. In Colombia, proportion of patients with undernutrition during course of pediatric HIV infection has not been recently determined. Latin American sources have reported a prevalence of malnutrition among children living with HIV that varies between 52.4% to 69.3% in countries such as Peru and Venezuela2,3. In Colombia, a hospital based study in Cali found that 72% of children infected with HIV by vertical transmission were underweight, 67% stunted and 35% wasted4, which is consistent with a 70.4% of children with underweight that was found in a University Hospital in Medellín5. However, it has been more than a decade since the
publication of those findings and Colombian nutritional panorama could have changed. The objective of this work is to describe nutritional status of pediatric patients infected with HIV in Bogota, and to explore a possible interaction between malnutrition and ART failure.

**Patients and methods**

Retrospective longitudinal descriptive study, in a simple of 28 patients belonging to HIV program of the outpatient clinic Asistencia Científica de Alta Complejidad SAS, in Bogota city. Variables were retrieved from clinical records between years 2012 and 2020. Given the exploratory nature of the study, sampling was made by convenience, gathering information of all pediatric patients who met two inclusion criteria: 1) A confirmed diagnosis of HIV, according to local guidelines and 2) An age of less than 18 years. In order to calculate Z scores of Weight for height (WHZ), height for age (HAZ), weight for age (WAZ) and BMI for age (BAZ) in children under 5 years, the software WHO Anthro v3.2.2 (OMS 2011, Geneva, Switzerland) was used. To calculate HAZ, WAZ and BAZ in children from 5 to 19 years of age, the software WHO AnthroPlus v1.0.4 (OMS 2009, Geneva, Switzerland) was used.

For nutritional diagnosis the following definitions were adopted:

- **Wasting or acute malnutrition:** WHZ < -2.
- **Stunting or chronic malnutrition:** HAZ < -2.
- **Underweight or global malnutrition:** WAZ < -2.
- **Thinness:** BAZ < -2\(^2\).

Different therapeutic failure definitions that were used can be consulted in supplementary material.

Variables were typed in the software Microsoft Excel 2016. Statistics were processed in the software STATA 13 MP-Parallel Edition for Windows. Differences among categorical variables were explored with Chi squared test or Fisher F test, and relative risks with 95% confidence intervals were estimated using a generalized linear model. Shapiro-Wilk normality test was applied and then differences were explored with non-paired Student t test, assuming equal variances, or Wilcoxon signed rank test. In spite of the assumption of a one-tailed p<0.05 as a limit to consider statistical significance, interpretation must be cautious, given the exploratory and hypothesis generating nature of this study, that was conceived from the moment of sampling calculation. In order to describe the longitudinal behavior of some variables, a comparison was made from the entry to the HIV program to 12 months later, with paired Student t test and McNemar marginal homogeneity test. Patients with missing data were excluded from respective analysis. Figures were generated using the software Prism 7 for Windows (GraphPad Software Inc, San Diego, CA, United States). As this research posed no risk for investigation subjects, no informed consent was obtained from recruited patients and data retrieved from clinical records were protected with confidentiality and privacy. An institutional Ethics Review Board superintended this process.

**Results**

36 clinical records met the inclusion criteria and 8 patients were excluded because of missing longitudinal anthropometric data in 5 of them, erroneous data in 1 patient and missing longitudinal immuno-virological data in another patient. One additional patient was excluded because of pregnancy. A total of 28 patients were included in this work.

In table 1, basal features at the moment of entry to the HIV program are shown. 21 out of 28 patients had vertical transmission of HIV (75%; 95%CI: 59 – 91), 9 (32,1%) had at least one non-HIV associated comorbidity, among which bronchiolitis, acute lymphoid leukemia and resolved B hepatitis were highlighted. On the other hand, 11 (39,3%) patients had opportunistic infections such as chronic diarrhea, recurrent pneumonia, oropharyngeal and esophageal candidiasis, herpes zoster and ganglionic tuberculosis. Only 7 (25%) patients were ART naive and time interval from HIV infection diagnosis to start of ART had a median of 22 days (intercuartil range: 4 – 74).

| Variable | Total (n=28) |
|----------|-------------|
| **Gender, n (%)** | | |
| Male | 19 (67.8) |
| Female | 9 (32.2) |
| Age ♂ | 8.76 (4.50) |
| Age category, n (%)\(^*\) | | |
| Less than 1 year | 2 (7.14) |
| 1 – 4.9 years | 5 (17.86) |
| 5 – 9.9 years | 10 (35.71) |
| 10 a 14.9 years | 9 (32.14) |
| More than 15 years | 2 (7.14) |
| **Height (cm) ♂** | 122.6 (28.1) |
| **BMI (Kg/m\(^2\)) ♂** | 16.6 (2.5) |
| **Anthropometric indices ♂** | | |
| WHZ | -0.87 (1.51) |
| HAZ | -1.12 (-1.63 - 0.52) |
| WAZ | -0.73 (1.95) |
| BAZ | -0.28 (1.37) |
| **Immuno-virological control markers ♂** | | |
| CD4 count (cells/UL) | 877 (682) |
| CD4 percentage | 32.65 (19.82) |
| Viral load (copies/ML) | 10893 (40 – 104187) |
| **Blood analytics ♂** | | |
| Hemoglobin (g/dL) | 13.6 (1.6) |
| Total cholesterol (mg/dL) | 150.9 (34.4) |
| HDL cholesterol (mg/dL) | 41.9 (16.8) |
| LDL cholesterol (mg/dL) | 81.4 (29.8) |
| Triglycerides (mg/dL) | 136 (55) |
| Creatinine (mg/dL) | 0.42 (0.32 – 0.59) |
| Estimated glomerular filtration rate (mL/min)\(^€\) | 113.9 (29) |

Anthropometric and paraclinical features of patients at the moment of entry to the HIV program are shown. n: number of subjects; BMI: Body mass index; WHZ: Weight for height Z score; HAZ: Height for age Z score; WAZ: Weight for age Z score; BAZ: BMI for age Z score; HDL: High density lipoprotein; LDL: Low density lipoprotein; §: Mean (SD). ¥: Median (ICR). * Frequency (%). €: Determined with Schwartz formula.\(^2\)
After a clinical follow-up interval elapsed, just 1 patient changed ART from zidovudine-lamivudine-efavirenz (AZT-3TC- EFV) to raltegravir-lamivudine-lopinavir/ritonavir (RAL-3TC-LPV/r) because of virological failure. 6 out of 28 patients suffered adverse events (AE) to ART (21,4%; 95%CI: 6,2 – 36,6%), such as LPV/r –associated vomiting in half of all cases and hypertriglyceridemia in the remaining half of affected patients. No AE led to treatment discontinuation. ART adherence was 82,1% (95%CI: 68 – 96,3). Percentage distribution of different ART is depicted in supplementary figure 1.

Most of patients were classified in clinical and immunological A1 category (supplementary table 1). Except for ART naïve patients, just 5 out of 21 (23,8%) participants had undetectable viral load at program entry. Proportion of patients with virological, immunological and clinical failure could be determined in all patients except for 7 of them who were ART naïve and 3 participants who had started ART less than 90 days before being recruited. After a mean clinical follow-up interval of 424 (SD: 82,5), virological, immunological and clinical failure outcomes were determined again, according to WHO, the Department of Health and Human Services of the United States and the Expert Panel of Spanish Society of Pediatric Infectology - National AIDS program standards; this time in all patients. The results are shown in supplementary figure 2; keeping in mind that there is neither a standardized definition of clinical failure in Spanish guidelines, nor a definition of immunological failure in North American guidelines.

After a paraclinical median follow-up period of 378 days (ICR: 310 to 459), changes in count and percentage of CD4 lymphocytes, viral load (figure 1) and CDC category (supplementary figure 3) were explored. In table 2, several important outcomes are compared at the program entry and after the follow-up period had elapsed. It is noteworthy, that 18 pairs of data were processed for analysis of immuno-virological outcomes shown in table 2. Pairs of data with missing values at baseline or during follow-up, were excluded from the analysis. As a result, relative risk (RR) and absolute risk reduction (ARR) statistics were calculated based on proportions of patients that differ from those shown in baseline and follow-up columns of table 3. In such columns, the percentage of the totality of available patients at a time is shown.

Baseline anthropometrical evaluation revealed that 4 out of 28 patients were stunted (14,3%; 95%CI: 1,3 – 27,2), 2 of them severely stunted (HAZ < -3); 2 out of 7 patients were wasted (28,6%; 95%CI: 0 – 62), 1 of them severely wasted (WHZ < -3); and 5 out of 17 patients were underweight (27,8%; 95%CI: 7,1 – 48,5), 1 of them severely underweight (WAZ < -3). According to BAZ, 4 out of 28 patients suffered thinness (29,6%; 95%CI: 12,4 – 46,8), 1 of them was severely thin (BAZ < -3). Changes in anthropometrical variables after clinical follow-up interval are shown in figure 2.

Anemia was found in 2 out of 8 girls and 11 out of 17 (64,7%) boys, adopting hemoglobin cut-off points from a reference laboratory (<12 g/dL for girls and <14 g/dL for boys). Considering reference values for diagnosis of dyslipidemia in children, baseline elevations in total cholesterol (TC), LDL cholesterol (LDLc) and triglycerides (TG) in 2 out of 22 (9,1%), 1 out of 22 (4,6%) and 16 out of 22 (72,7%) patients, respectively. A low HDL cholesterol (HDLc) value was found in 10 out of 21 (47,6%) patients. No patients had an estimated glomerular filtration rate (eGFR) below 60 mL/min, making use of the last update of Schwartz formula.

After a paraclinical follow-up interval, an increment in mean value of TC, mainly due to LDLc was found (p=0,0063), with no significant changes in HDLc, TG or hemoglobin. Serum creatinine increased during paraclinical follow-up interval (p=0,0019), parallel to a decrease in mean eGFR from 116 mL/min to 105 mL/min (p=0,0109). Finally, mean changes of several clinical-anthropometrical and paraclinical nutritional diagnosis are shown in table 2.

**Discussion**

In this work, malnutrition was found to be a frequent comorbidity in pediatric patients living with HIV in Bogota, Colombia. The WHO Nutritional Landscape Information System has defined prevalence cut-off points to establish the impact that several nutritional diagnosis have on the public health of a nation. According to this information, the prevalence of wasting found in this work is categorized as critic (>15%), proportion of patients with underweight is catalogued as high (20-29%), while the percentage of patients with stunting seems to be...
The percentage of children with underweight that was found more than a decade ago in different Colombian cities (70.4 - 72%) is high in comparison with the upper limit of the confidence interval found in the present study (27.8%; 95%CI: 7.1 - 48.5). Likewise, a previous proportion of children with stunting of 67% in 2005, is high in comparison with the currently found one (14.3%; 95%CI: 1.3 - 27.2). Nonetheless, a prevalence of wasting found in that same work from Cali seems to be similar to the one reported in this research (28.6%; 95%CI: 0 - 62). Several reasons explain this improvement in the nutritional status. According to the Nutritional Situation National Survey of Colombia (ENSIN, from its Spanish initials), Between years 2005 to 2015 pediatric chronic malnutrition decreased 5.2% for children under 5 years and 6.5% for children between 5 and 12 years of age. In the same way, between years 2017 and 2018 there was a paramount 24% increment in ART national coverage for children between 0 and 14 years. In view of the above, it is plausible that malnutrition prevalence in children living with HIV in Bogotá may be decreasing, although further research is required to confirm such assertion.

In the present research there were no clinically significant longitudinal changes in anthropometrical markers, which is in contrast with previous findings from published cohort studies that show a sustained improvement of every Z score (WHZ, HAZ, WAZ and BAZ) throughout the first year from start of ART, with a subsequent stabilization of the markers during the following 5 years of follow-up. In this way, the current work is consistent with previous findings because of, except for ART naive patients, 18 out of 21 patients (85.7%) were already receiving ART with a therapy duration greater or equal to one year, and therefore they were out of the nutritional benefit window of the first year from ART starting point.

There was no significant variation in the percentage of patients with therapeutic failure during follow-up and the proportion was comparable with the one found in two Thai prospective cohorts and a study from Netherlands, notwithstanding the use of different definitions. However, it is noteworthy that the percentage of patients with undetectable viral load was so low even after the paraclinical time interval had elapsed (35.7%; 95%CI: 18.5 - 3.5). A meta-analysis of 12 publications, with a total of 1497 patients from developing countries, estimated in 70% (95%CI: 6 - 73) the proportion of patients with undetectable viral load at one year from ART start. One possible explanation of this contrast is the detection limit of viral load assay, which is < 20 copies/mL for the present study. If the cut-off point from the above cited studies (< 50 copies/mL) is used instead, the proportion of patients with viral suppression increases to 53.6%. The reason for the finding of a low proportion of patients with undetectable viral load could be explored in future local studies.

The fact that the finding of a percentage CD4 increment (∆CD4) of 5.9% (95%CI: 1.6 - 10) was inferior to the 14% (95%CI: 12 - 16) reported in the Ciaranello, et al meta-analysis, is explained because of the exclusion of studies with ART experienced patients in the cited meta-analysis, which stand for the majority of the studied population in the present work. Previous research has confirmed a marked increase in CD4 percentage throughout the first year of ART, a change that is much lower and seems to stabilize in subsequent years of therapy continuation, as observed in this work, whose ART experienced population had a median therapy duration of 5.5 years (ICR: 1.6 - 9.1) at HIV program entry.

It is well known that protease inhibitors (PI) increase very low density lipoprotein cholesterol (VLDLc) production in the liver and decrease peripheral retrieval of triglycerides. Despite that in the present work, more than 80% of patients received LPV/r (supplementary figure 1), It is remarkable that the percentage of patients with hypertriglyceridemia and total hypercholesterolemia is similar to the one found in an observational study, whose children population received treatments without PI in 100% of cases. It is likely that, because of the use of different cut-offs for diagnosis of dyslipidemia, it may not be possible to draw valid conclusions from this comparison. In contrast, a previously found prevalence of low HDLc of 3.7% in patients treated with nevirapine (NVP) based regimens is much lower than the one found in this study, which was estimated around 50%. Anti-atherogenic properties attributed to NVP-based regimens lead to an
Among limitations of this work, a low number of patients is highlighted; which notwithstanding, does not hinder the hypothesis-generating capacity of a study designed with an exploratory nature. Numerous nutritional, anthropometrical and paraclinical variables were not found in accessed clinical records, which limits the descriptive potential of the whole nutritional panorama. As a retrospective study, the possibility of a confusion bias is not excluded, and a multivariable analysis to deal with that systematic error was not considered appropriate due to a low number of patients. A selection bias is possible, given that all patients belong to a subsided insurance regimen and come from a unique HIV program in the city, which must be kept in mind for generalization of the findings. Finally, an information bias in clinical records is also possible, although paraclinical information was corroborated directly in the clinical laboratory database and a double audit typed information was done. In the same way, it is stressed that there were no missing data in the principal variables; by which, it is not probable that the conclusions of the current work may be affected because of missing values.

In conclusion, undernutrition is frequent among children living with HIV in Bogotá and it is plausible that its prevalence had decreased through time, hand-in-hand with a change in other development indices of the country. Inclusion of patients in an HIV program was associated with an improvement in medical control of the disease, with stable therapeutic failure rates that are comparable to what has been found.

Table 2. HIV program follow-up effect on different nutritional outcomes of pediatric patients in Bogota, Colombia.

| Immunovirological outcomes according to WHO (baseline n= 18; follow-up n=28)* | Baseline | Follow-up | ARR (95%CI) | RR (95%CI) | NNT (95%CI) | p (one tail)* |
|---|---|---|---|---|---|---|
| Virological failure | 5 (27,8) | 6 (21,4) | -0,167 (-0,453, 0,120) | 0,4 (0,100, 1,6) | NS | 0,219 |
| Immunological failure | 1 (5,6) | 5 (17,9) | 0,222 (-0,025, 0,470) | 5 (0,866, 28,9) | NS | 0,062 |
| Clinical failure | 1 (5,6) | 2 (7,1) | 0,056 (-0,053, 0,171) | 2 (0,5, 0,8) | NS | 0,5 |

| Anthropometrical nutritional outcomes (n varies across categories §) |
|---|---|---|---|---|---|
| Stunting (HAZ < -2) (n=28) | 4 (14,3) | 4 (14,3) | 0 (-0,207, 0,207) | 1 (0,301, 3,32) | NS | 0,688 |
| Underweight (WAZ < -2) (baseline n=17; follow-up n=11) | 5 (27,8) | 3 (27,3) | -0,091 (-0,352, 0,17) | 0,75 (0,426, 1,32) | NS | 0,5 |
| Wasting (WHZ < -2) (baseline n=7; follow-up n=5) | 2 (29,4) | 1 (20) | 0,2 (-0,751, 0,351) | 0,5 (0,125, 2) | NS | 0,5 |
| Thinness (BAZ < -2) (n=28) | 4 (14,3) | 0 (0) | -0,143 (-0,308, 0,022) | 0 | NS | 0,062 |

| Paraclinical nutritional outcomes (n varies across categories §) |
|---|---|---|---|---|---|
| Anemia (baseline n=25; follow-up n=26) | 13 (52) | 11 (42,3) | -0,087 (-0,246, 0,072) | 0,83 (0,647, 1,07) | NS | 0,25 |
| High total cholesterol (baseline n=22; follow-up n=23) | 2 (9,1) | 9 (39,1) | 0,167 (-0,167, 0,5) | 2,5 (0,485, 12,9) | NS | 0,289 |
| High LDL cholesterol (baseline n=22; follow-up n=24) | 1 (4,5) | 8 (33,3) | 0,2 (-0,025, 0,425) | 5 (0,866, 28,9) | NS | 0,662 |
| Low HDL cholesterol (baseline n=21; follow-up n=23) | 10 (47,6) | 8 (34,8) | -0,111 (-0,428, 0,206) | 0,78 (0,425, 1,42) | NS | 0,453 |
| Hypertriglyceridemia (baseline n=22; follow-up n=24) | 16 (72,7) | 20 (83,3) | -0,053 (-0,282, 0,177) | 0,94 (0,753, 1,17) | NS | 0,625 |

Effect size of HIV program on different clinical and paraclinical outcomes. ¥: Baseline n is lower because of exclusion of ART naive patients; however, for ARR and RR estimating purposes, the number of pairs of data was 18. £: Baseline n is lower because patients exited the age group they belonged to during follow-up. §: Pairs of data with missing values at baseline or during follow-up were excluded from analysis. π: Baseline and follow-up n differ because of missing data. *A mid-p value of McNemar test was used, because the number of discordant pairs was lower than 25. ARR: Absolute risk reduction; RR: Relative risk; NNT: Number needed to treat; n: number of observations.
in other parts of the globe. However, frequent problems such as anemia and dyslipidemia remain being a therapeutic challenge for this group of patients with HIV.

Ethical disclosures

Protection of human and animal subjects. No experiments were performed in animal nor humans.

Confidentiality of data. Patient’s data were anonymized

Competing interests. None declared.

Ethical approval. This research was approved by the Ethics Committee of the University.

Conflict of interest. The authors have no conflicts of interest to declare.

Funding. This research has not received funding or specific help neither from public or commercial agencies nor from non-profit entities.

References

1. Jesson J, Leroy V. Challenges of malnutrition care among HIV-infected children on antiretroviral treatment in Africa. Med Mal Infect. 2015; 45: 149-56. 10.1016/j.medmal.2015.03.002
2. Villalobos-Colina D, García D, Bravo-Herrnriquez A. Estado Nutricional Antropométrico por Estrato Social en Niños con Síndrome de Inmunodeficiencia Adquirida. Antropo. 2012; 26: 29-36.
3. Miranda E, Farfán S, Barrientos S, Lara L, Cos D. Estado nutricional y aspectos familiares en niños peruanos con VIH en la era TARRA. Ciencia y Desarrollo. 2013; 16: 87-94. 10.21503/cydv161.1122
4. Velasco CA, Lopez P, Contreras LI. Anthropometric nutritional status in children HIV positive with vertical transmission: 51. Journal of Pediatric Gastroenterology and Nutrition. 2005; 41: 508-9. 10.1097/00002030-200112070-00008
5. Bustamante A, Elorza M, Cornejo W. Características clínicas de niños infectados por VIH atendidos en un hospital universitario en Medellín, Colombia. 1997-2005. Iatreia. 2007; 20: 354-61.
6. Ministerio de Salud y Protección Social de Colombia. Guía de Práctica Clínica basada en la evidencia científica para la atención de la infección por VIH en Colombia, 1997-2005. https://www.icbf.gov.co/bienestar/bienestar_nutricion/pdf/GPC_VIH_ninos/GPC_completa_VIHpediatrica.pdf. (Accessed: 10/02/2021).
7. WHO Expert Committee on Physical Status. Physical status : the use of and interpretation of anthropometry, report of a WHO expert committee. Geneva: World Health Organization 1995. https://apps.who.int/iris/handle/10665/37003. (Accessed: 10/02/2021).
8. Cole TJ, Flegal KM, Nicholls D, Jackson AA. Body mass index cut offs to define thinness in children and adolescents: international survey. BMJ. 2007; 335: 194-. 10.1136/bmj.39238.39944.55
9. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009; 4: 1832-43. CJN.01640309 [pii] 10.2215/CJN.01640309
10. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. 2013: 269. https://www.who.int/hiv/pub/arv-arv-2016/en/ (Accessed: 10/02/2021).
11. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. United States of America: Department of Health and Human Services 2020. https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines. (Accessed: 10/02/2021).
12. Panel de expertos de la Sociedad Española de Infectología Pediátrica (SEIP) y del Plan Nacional sobre el SIDA (PNS). Documento de consenso sobre tratamiento antirretroviral en niños y adolescentes con infección por el virus de la inmunodeficiencia humana. 2019. https://www.aeped.es/documentos/documento-consenso-sobre-tratamiento-antirretroviral-en-ninos-y-adolescentes-infecados-por-vih. (Accessed: 10/02/2021).
13. Expert Panel on Integrated Guidelines for Cardiovascular Health Risk Reduction in Children and Adolescents, National Heart Lung Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011; 128 Suppl 5: S213-S56. 10.1542/peds.2009-2107C
14. WHO. Nutrition Landscape Information System (NLIS) country profile indicators interpretation guide. Geneva: World Health Organization 2010. https://apps.who.int/iris/handle/10665/44397. (Accessed: 10/02/2021).
15. Instituto Colombiano de Bienestar Familiar. ENSIN: Encuesta nacional de salud nutricional en Colombia. 2015. https://www.icbf.gov.co/bienestar/nutricion/encuesta-nacional-situacion-nutricional#ensin. (Accessed: 10/02/2021).
16. ONUSIDA. Country Fact-sheets for Colombia. 2019. https://www.unaids.org/es/regioncountrys/countries/colombia. (Accessed: 10/02/2021).
17. Jesson J, Ephoevi-Ga A, Desmond S, et al. Growth in the first 5 years after antiretroviral therapy initiation among HIV-infected children in theleDEA West African Pediatric Cohort. Trop Med Int Health. 2014; 29. 775-85. 10.1111/tmi.12337
18. Guillén S, Ramos JT, Resino R, Bellón JM, Muñoz MA. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J. 2007; 26: 4. 10.1097/01.inf.0000257427.19764 ff
19. Cohen S, van Bilzen Wp Fau - Smit C, Smit C Fau - Kraaij PLA, et al. Country of birth does not influence long-term clinical, virologic, and immunological outcome of HIV-infected children living in the Netherlands: a cohort study comparing children born in the Netherlands with children born in Sub-Saharan Africa. J Acquir Immune Defic Syndr. 2015; 68: 7. 10.1097/QAI.000000000000431
20. Bunupuradah T, Puthanakit T, Kosalaraksa P, et al. Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children. AIDS Res Ther. 2011; 8: 40-. 10.1186/1742-6405-8-40
21. Ciarennolo AL, Chang Y, Margulis AV, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009; 49: 1915-27. 10.1086/648079
22. Kamin D, Hadigan C. Hyperlipidemia in children with HIV infection: an emerging problem. Expert Rev Cardiovasc Ther. 2003; 1: 7. 10.1586/14779072.1.1.143
23. Abebe M, Kinde S Fau - Belay G, Belay G Fau - Gebreghiabziaber A, et al. Antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia: a cross-sectional comparative study. BMC Res Notes. 2014; 7. 10.1186/1756-0500-7-380
24. Mandal A, Mukherjee A, Lakshmy R, Kabra SK, Lodha R. Dyslipidemia in HIV-infected children: severity, types and effect on response to HAART. Indian J Pediatr. 2016; 83: 5. 10.1007/s12098-015-1859-3
25. van der Valk M, Kastelein JJ Fau - Murphy RL, Murphy Rl Fau - van Leth F. No experiments were performed in animal nor humans. 10.1111/tmi.13237
26. van der Valk M, Kastelein JJ Fau - Murphy RL, Murphy Rl Fau - van Leth F, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001; 15: 7. 10.1097/00002030-200112070-00008
27. Nampijja D, Kumbukumba E, Bajunirwe F, Kwanjuka J. Dyslipidemia and its Correlates among HIV Infected Children on HAART Attending Mbarara Regional Referral Hospital. Int Clin Pathol J. 2017; 4. 10.15406/icpjl.2017.04.00098
28. Wagnev F, Esthete S, Abele B, et al. Burden of anemia and its association with HAART in HIV infected children in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2019; 19. 10.1186/s12879-019-4656-1
29. Anyabolu HC, Adejuyigbe EA, Adeodu OO. Undernutrition and anaemia among HAART-naive HIV infected children in Ile-Ife, Nigeria: a case-controlled, hospital based study. Pan Afr Med J. 2014; 24.
30. Nyesigire Ruhindu E, Bajunirwe F Fau - Kwanjuka J, Kwanjuka J. Anaemia in HIV-infected children: severity, types and effect on response to HAART. BMC Pediatr. 2012; 12. 10.1186/1471-2431-12-170
31. Mocroft A, Kirk O Fau - Barton SE, Barton Se Fau - Dietrich M, et al. Anaemia is an independent predictive marker for clinical diagnosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS. 1999; 13: 7. 10.1007/0-387-99905-280-00010

